Nilotinib monotherapy induced complete remission in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to imatinib and dasatinib

Leuk Lymphoma. 2014 Jul;55(7):1652-3. doi: 10.3109/10428194.2013.842984. Epub 2013 Nov 1.

Authors

Masahiro Sekimizu¹, Yuka Yamashita, Hideaki Ueki, Nobuhiro Akita, Hiroyoshi Hattori, Naoko Maeda, Keizo Horibe

Affiliation

¹ Department of Pediatrics.

PMID: 24024475
DOI: 10.3109/10428194.2013.842984

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Agents / therapeutic use*
Bone Marrow Transplantation
Child
Dasatinib / pharmacology
Dasatinib / therapeutic use
Drug Resistance, Neoplasm
Humans
Imatinib Mesylate / pharmacology
Imatinib Mesylate / therapeutic use
Male
Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
Protein Kinase Inhibitors / therapeutic use*
Pyrimidines / therapeutic use*
Remission Induction
Treatment Outcome

Substances

Antineoplastic Agents
Protein Kinase Inhibitors
Pyrimidines
Imatinib Mesylate
nilotinib
Dasatinib